The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia von Islamagic, Erna, Hasic, Azra, Kurtovic, Sabira, Suljovic Hadzimesic, Emina, Mehinovic, Lejla, Kozaric, Mirza, Kurtovic-Kozaric, Amina

Volltext

The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina von Kozaric, Amina Kurtovic, Islamagic, Erna, Radich, Jerald P., Suljovic Hadzimesic, Emina, Hasic, Azra, Kurtovic, Sabira

Volltext

Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era von Sofo-Hafizovic, Alma, Chikha, Adisa, Gojak, Refet, Hadzimesic, Emina Suljovic

Volltext

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients von Islamagic, Erna, Ms, Hasic, Azra, MD, Kurtovic, Sabira, MD, Hadzimesic, Emina Suljovic, MD, Mehinovic, Lejla, Ms, Kozaric, Mirza, MD, Kurtovic-Kozaric, Amina, PhD

Volltext

Successful collection of stem cells in one day in the process of autologous stem cell transplantation von Sofo-Hafizovic, Alma, Dizdarevic-Rekic, Aida, Ibricevic-Balic, Lejla, Burazerovic, Lejla, Vila, Meliha, EminaSuljovic-Hadzimesic, Skuric-Tomic, Marina, Catovic-Baralija, Elma, Ahmetovic, Gorana, Sahovic, Amela, Sicanica, Sanela, Omanovic, Amina

Volltext